Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial.

diabetes mellitus mobile health randomized controlled trial treatment adherence type 2 diabetes

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
30 May 2019
Historique:
received: 12 10 2018
accepted: 25 03 2019
revised: 09 03 2019
entrez: 15 6 2019
pubmed: 15 6 2019
medline: 15 6 2019
Statut: epublish

Résumé

Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added to usual care is limited. The objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving health outcomes and medication adherence in patients with type 2 diabetes compared to an active control. We will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6 weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin A Recruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in June 2019, followed by analysis and disclosing of group allocation. The knowledge gained from this study will have wide applications and advance the evidence base for effectiveness of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for informing people about the work and raise awareness of what is being developed and studied. ISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808 (Archived by WebCite at http://www.webcitation.org/786316Zqk). DERR1-10.2196/12377.

Sections du résumé

BACKGROUND BACKGROUND
Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added to usual care is limited.
OBJECTIVE OBJECTIVE
The objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving health outcomes and medication adherence in patients with type 2 diabetes compared to an active control.
METHODS METHODS
We will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6 weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin A
RESULTS RESULTS
Recruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in June 2019, followed by analysis and disclosing of group allocation.
CONCLUSIONS CONCLUSIONS
The knowledge gained from this study will have wide applications and advance the evidence base for effectiveness of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for informing people about the work and raise awareness of what is being developed and studied.
TRIAL REGISTRATION BACKGROUND
ISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808 (Archived by WebCite at http://www.webcitation.org/786316Zqk).
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
DERR1-10.2196/12377.

Identifiants

pubmed: 31199346
pii: v8i6e12377
doi: 10.2196/12377
pmc: PMC6592392
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12377

Subventions

Organisme : Medical Research Council
ID : MR/M016498/1
Pays : United Kingdom

Informations de copyright

©Andrew Farmer, Kirsty Bobrow, Natalie Leon, Nicola Williams, Enita Phiri, Hazel Namadingo, Sara Cooper, John Prince, Amelia Crampin, Donela Besada, Emmanuelle Daviaud, Ly-Mee Yu, Jonathan Ngoma, David Springer, Bruno Pauly, Shane Norris, Lionel Tarassenko, Moffat Nyirenda, Naomi Levitt. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 30.05.2019.

Références

Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
J Psychosom Res. 1999 Dec;47(6):555-67
pubmed: 10661603
Health Policy Plan. 2001 Sep;16(3):326-31
pubmed: 11527874
Clin Sci (Lond). 2001 Dec;101(6):671-9
pubmed: 11724655
Diabetes Care. 2004 Dec;27(12):2800-5
pubmed: 15562188
Soc Sci Med. 2005 Jul;61(1):133-55
pubmed: 15847968
Value Health. 2007 Jan-Feb;10(1):3-12
pubmed: 17261111
BMJ. 2007 Mar 3;334(7591):455-9
pubmed: 17332585
Milbank Q. 2007 Jun;85(2):185-208; discussion 209-12
pubmed: 17517112
Health Aff (Millwood). 2007 Jul-Aug;26(4):1197-8
pubmed: 17630466
BMC Health Serv Res. 2008 Oct 09;8:210
pubmed: 18844998
AIDS Care. 2010 Jan;22(1):1-9
pubmed: 20390475
Clin Ther. 2011 Jan;33(1):74-109
pubmed: 21397776
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
PLoS One. 2012;7(9):e43336
pubmed: 22962583
Glob Health Action. 2013 Jan 24;6:19244
pubmed: 23364089
PLoS Med. 2013;10(1):e1001363
pubmed: 23458994
Ann Behav Med. 2013 Aug;46(1):81-95
pubmed: 23512568
Lancet Diabetes Endocrinol. 2013 Nov;1(3):191-8
pubmed: 24622367
JAMA. 2014 Apr 23-30;311(16):1693
pubmed: 24756524
BMC Endocr Disord. 2014 May 12;14:41
pubmed: 24884894
BMC Fam Pract. 2015 Jul 03;16:80
pubmed: 26137844
Diabetes Care. 2015 Aug;38(8):e112-3
pubmed: 26207059
Diabet Med. 2016 May;33(5):565-79
pubmed: 26470750
Circulation. 2016 Feb 9;133(6):592-600
pubmed: 26769742
J Med Internet Res. 2016 Apr 19;18(4):e86
pubmed: 27095386
J Med Internet Res. 2017 Jun 29;19(6):e232
pubmed: 28663162
J Clin Transl Endocrinol. 2017 Jan 03;7:33-41
pubmed: 29067248
BMC Health Serv Res. 2018 Jan 23;18(1):33
pubmed: 29361934
BMJ. 2018 May 17;361:k1959
pubmed: 29773539
BMC Public Health. 2018 Sep 29;18(1):1148
pubmed: 30268115

Auteurs

Andrew Farmer (A)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Kirsty Bobrow (K)

Chronic Disease Initiative for Africa, University of Cape Town, Cape Town, South Africa.

Natalie Leon (N)

South African Medical Research Council, Cape Town, South Africa.

Nicola Williams (N)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Enita Phiri (E)

Malawi Epidemiology and Intervention Research Unit, Lilongwe, Malawi.

Hazel Namadingo (H)

Malawi Epidemiology and Intervention Research Unit, Lilongwe, Malawi.

Sara Cooper (S)

South African Medical Research Council, Cape Town, South Africa.

John Prince (J)

Institute of Biomedical Engineering, Oxford, United Kingdom.

Amelia Crampin (A)

Malawi Epidemiology and Intervention Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Donela Besada (D)

South African Medical Research Council, Cape Town, South Africa.

Emmanuelle Daviaud (E)

South African Medical Research Council, Cape Town, South Africa.

Ly-Mee Yu (LM)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Jonathan Ngoma (J)

Kamuzu Central Hospital, Lilongwe, Malawi.

David Springer (D)

The Boston Consulting Group, London, United Kingdom.

Bruno Pauly (B)

Department of Diabetes and Endocrinology, Chris Hani Baragwanath Academic Hospital, Johanesburg, South Africa.

Shane Norris (S)

South African Medical Research Council, Developmental Pathways for Health Research Unit, University of Witwatersrand, Johannesburg, South Africa.

Lionel Tarassenko (L)

Institute of Biomedical Engineering, Oxford, United Kingdom.

Moffat Nyirenda (M)

Malawi Epidemiology and Intervention Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Naomi Levitt (N)

Chronic Disease Initiative for Africa, University of Cape Town, Cape Town, South Africa.

Classifications MeSH